louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04591327: Atelectasis by Lung Ultrasonography in Cesarean Sections
Official title: Determination of the Effects of General Anesthesia and Spinal Anesthesia Applied in Elective Cesarean Operations on Postoperative Atelectasis by Lung Ultrasonography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atelectasis
Cesarean Section
Lead sponsor: Derince Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-10-19
Enrollment: 46
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Between 18-40 years old, 37-40 weeks pregnant, ASA II because of pregnancy.

Brief summary: In this study aimed to demonstrate that atelectasis developing in the perioperative period of patients undergoing elective cesarean surgery with spinal or general anesthesia methods using lung ultrasound. After Preoperative lung ultrasounds of patients is done, the cesarean operation will be completed with spinal or general anesthesia. In the postoperative period, control lung ultrasounds will be performed and the ultrasound results will be compared in terms of atelectasis in both groups.


Eligibility criteria: Inclusion Criteria:

* Between 18-40 years
* 37-40 weeks pregnant
* ASA II because of pregnancy

Exclusion Criteria:

* Emergency cesarean sections
* who refuse to participate in the study
* with chronic disease
* Smoker
* with chest deformity

Primary outcomes:
measure: incidence of the postoperative atelectasis
timeFrame: two months
Secondary outcomes:
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli Derince Train and Research Hospital
Study officials:
References:
Clinical trial NCT00677027: Dose Escalation Safety Study of MM-10-001 in Healthy Subjects
Official title: Dose Escalation Safety Study of MM-10-001
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy
Keywords: Beta-glucan
immune system
Healthy subjects
Lead sponsor: GlycaNova Norge AS
Sponsor class: INDUSTRY
Collaborators: name: Centre for clinical studies, Bergen, Norway
First posted: 2008-05-13
Enrollment: 50
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the safety of increasing doses of MM-10-001 and to determine the dose of MM-10-001 that enhances the immune system in normal healthy subjects.

Detailed description: The drug substance to be studied is a powder produced from shiitake mushroom, containing beta-glucans. The purpose of this study is to evaluate the safety of increasing doses of MM-10-001 and to determine the dose of MM-10-001 that enhances the immune system in normal healthy subjects.

Eligibility criteria: Inclusion Criteria:

Healthy subjects of both genders, age \> 45 years old will be eligible for study.

Exclusion Criteria:

Subjects who:

1. Fail to give written informed consent
2. Have BMI over or equal to 30 kg/m2
3. Use corticosteroids (including inhaled steroids) or NSAIDs anti-inflammatory drugs
4. Have uncontrolled hypertension (sitting diastolic blood pressure\>95 mmHg)
5. Have on-going allergy or history of anaphylactic reaction
6. Have on-going allergen specific immunotherapy
7. Are immuno-compromised (HIV infected, cancer and other disease affecting the basal immune response)
8. Have chronic inflammatory disease
9. Have diabetes (type 1 or type 2)
10. Have chronic severe renal disease (creatinine outside normal range)
11. Have chronic severe liver disease (ASAT and/or ALAT more than two times the upper limit of the normal range)
12. Have known cardiac failure
13. Have recently (less than 6 months) experienced myocardial infarction
14. Have gastrointestinal diseases (chronic gastritis, IBD, etc.)
15. Have acute or chronic pancreatitis or impaired pancreatic function, or history of pancreatitis
16. Have been vaccinated within the last three months
17. Eat diet supplement NG24 beta-glucan
18. Eat shiitake cheese
19. Have systemic fungal infection
20. Have any clinical condition that renders them unfit to participate including known/suspected drug or alcohol abuse
21. Do not fully understand the content of the informed consent
22. Pregnant and lactating women or women of childbearing potential not using adequate contraception.

Primary outcomes:
measure: Blood safety parameters
timeFrame: every second week
Secondary outcomes:
measure: Cell mediated immune response and cytokine production
timeFrame: every second week
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Centre for clinical studies
state: Paradis
Study officials:
affiliation: Centre for clinical studies, Bergen, Norway
name: Snorre Ofjord, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01191827: fMRI Cholinergic Mechanisms in Schizophrenia
Official title: fMRI Cholinergic Mechanisms in Schizophrenia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2010-08-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with schizophrenia

Brief summary: This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.

Detailed description: This study will use functional magnetic resonance imaging (fMRI) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of schizophrenia
* age 18-60 yrs

Exclusion Criteria:

* claustrophobia
* weight \> 250 lbs
* metal in body other than dental fillings

Primary outcomes:
measure: Neuronal Response During Sensory Gating
timeFrame: Immediate
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: VA Eastern Colorado Health Care System, Denver
state: Colorado
Study officials:
affiliation: VA Eastern Colorado Health Care System, Denver
name: Jason R. Tregellas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00703027: Diabetes Mellitus Care Decision Making Model Through Data Mining
Official title: Diabetes Mellitus Care Decision Making Model Through Data Mining
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Keywords: diabetes mellitus
care decision
data mining
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
Collaborators: name: National Taiwan University
First posted: 2008-06-20
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective cohort study included 2,000 patients who visited our Division of Endocrinology and Metabolism outpatient department in this hospital with the diagnosis diabetes mellitus who had been enrolled into the Diabetes Care Program from year 2002 until 2007.

Brief summary: We tried to use data mining method to find out the new model of factors that affects the progression of diabetes mellitus.

Detailed description: The advanced development of medical technology had led to the accumulation of a large amount of medical data. Unfortunately, these useful and meaningful clinical data were not properly managed or analyzed. Therefore, data mining technology has become an essential instrument for hospital management and medical research. Possible meaningful information can be obtained from the database through data mining. About 2,000 diabetic patients had been enrolled in Diabetes Care Program since Oct 2002 in our hospital. We intend to look for the determining factors that affect the prognosis of diabetes mellitus in our patients group.

Eligibility criteria: Inclusion Criteria:

* diabetes mellitus who had been enrolled into the Diabetes Care Program from year 2002 until 2007.

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Far Eastern Memorial Hospital
name: Jiang Ju Ying, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02624427: Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST Tonometer
Official title: Comparison of Intraocular Pressure Measured by Goldmann Applanation Tonometry and Dynamic Contour Tonometry vs. Corvis ST Tonometer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: Glaucoma
Intraocular Pressure
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2015-12-08
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The study is investigating Intra ocular pressure (IOP) by Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and the Corvis ST tonometer.

Detailed description: The aim of the study is to approach the "true" Intra ocular pressure (IOP) by correlating the difference between IOP by Goldmann Applanation Tonometry to the IOP by Dynamic Contour Tonometry to the biomechanical parameters of the cornea measured by Corvis ST. Therefore the investigators gain new findings about the influence of the biomechanical corneal parameters on the IOP. In order to do so the investigators want to examine 50 Glaucoma eyes and 50 non-Glaucoma Eyes with Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST.

Eligibility criteria: Inclusion Criteria for the glaucoma group:

* diagnosis of glaucoma
* 18 years old or older with no upper limit

Exclusion Criteria for the glaucoma group:

* IOP lowering surgery within the last 3 weeks
* any corneal surgery in the past
* bad fixation
* insufficient measurement quality with any of the study devices

Inclusion Criteria for the healthy control group:

* no diagnosis of glaucoma
* 18 years old or older with no upper limit

Exclusion Criteria for the healthy control group:

* any diagnosis of glaucoma
* IOP lowering surgery within the last 3 weeks
* any corneal surgery in the past
* bad fixation
* insufficient measurement quality with any of the study devices

Primary outcomes:
measure: Delta IOP
timeFrame: baseline
Secondary outcomes:
measure: Correlation of IOP difference of Goldmann tonometer and Dynamic Contour tonometer with biomechanical corneal properties measured by Corvis ST tonometer
timeFrame: baseline
Other outcomes:
Locations:
Study officials:
affiliation: UniversityHospital of Zurich, Zurich, Switzerland
name: Jens Funk, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04657627: FOODS: Food shOppers' sOcial meDia Study
Official title: FOODS: Food shOppers' sOcial meDia Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eating Behaviour of Discretionary Foods
Cognitive Restraint of Eating
Physical Activity
Body Weight
Keywords: Nutrition labelling
Physical activity
Social media
Lead sponsor: Loughborough University
Sponsor class: OTHER
Collaborators: name: Dr Oonagh Markey
name: Alexandra Todd
First posted: 2020-12-08
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomised to one of two groups for 13 weeks: (i) PACE plus calorie information intervention group or (ii) calorie-only information comparator group.
Primary purpose: PREVENTION

Brief summary: This study aims to assess the effects of a new approach to food labelling called physical activity calorie equivalent (PACE) labelling. PACE food labelling provides the public with information about how many minutes (or miles/kilometres) of physical activity (e.g. walking or running) are equivalent to the calories contained in foods.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years old.
* BMI of ≥ 18.5 kg/m2.
* ≤ 3kg weight loss in previous 6 months.
* Access and ability to use personal Twitter and/or Instagram account via own smartphone, computer or tablet device.
* Access to the internet.
* Access to a set of weighing scales.

Exclusion Criteria:

* Unable to read and understand English.
* Experienced in the last 12 months or currently undergoing any of the following conditions or illnesses: coronary heart disease (CHD), hypertension, heart failure, stroke/transient ischaemic attack, atrial fibrillation, type 2 diabetes, chronic obstructive pulmonary disease (COPD), painful condition, dementia and cancer.
* Had bariatric surgery.
* Pregnant, lactating or planning to become pregnant in the next 12 months.
* Parallel participation in another weight, dietary or physical activity intervention study.

Primary outcomes:
measure: Change in eating behaviour of discretionary foods at 13 weeks
timeFrame: Pre-baseline (one time point prior to randomisation) and post-intervention (one time point after week 13)
Secondary outcomes:
measure: Cognitive restraint of eating
timeFrame: Pre-baseline (one time point prior to randomisation) and post-intervention (one time point after week 13)
measure: Physical activity
timeFrame: Pre-baseline (one time point prior to randomisation) and post-intervention (one time point after week 13)
measure: Body weight
timeFrame: Pre-baseline (one time point prior to randomisation), mid-intervention (week 7) and post-intervention (one time point after week 13)
Other outcomes:
Locations:
city: Loughborough
country: United Kingdom
facility: Loughborough University
state: Leicestershire
Study officials:
affiliation: Loughborough University
name: Amanda Daley
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06096727: The Energize! Study for Adults with Knee Replacement
Official title: Energize! Internet-Delivered Physical Activity Program for Adults with Knee Replacement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Arthroplasty
Keywords: physical activity
Lead sponsor: University of South Carolina
Sponsor class: OTHER
First posted: 2023-10-24
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose is to examine the effects of an online physical activity program on moderate to vigorous intensity physical activity, pain, and physical function in adults with knee replacement at 3 months (post-intervention) and 6 months (maintenance).

Detailed description: Participants with knee replacement will be randomized to start the online physical activity program (Energize!) either immediately or after 3 months. The online program consists of weekly physical activity goals, video lessons, action planning, and homework to help increase physical activity to 200 min/week. Assessments will be completed at baseline, 3 months, and 6 months.

Eligibility criteria: Inclusion Criteria:

* Have had a partial or total knee replacement ≥12 months ago
* Have regular access to the internet
* Willing to wear activity monitor for 7 days at baseline, 3 \& 6 months
* Engage in less than 60 minutes of self-reported moderate intensity exercise

Exclusion Criteria:

* Have a mobility limiting comorbidity
* Non-English speaking
* Have a scheduled surgery within the next 6 months that would limit activity

Primary outcomes:
measure: Minutes of moderate to vigorous intensity physical activity
timeFrame: baseline to 3 months
measure: Pain intensity
timeFrame: baseline to 3 months
measure: Self-reported physical function
timeFrame: baseline to 3 months
Secondary outcomes:
measure: Minutes of moderate to vigorous intensity physical activity
timeFrame: 3 months to 6 months
measure: Pain intensity
timeFrame: 3 months to 6 months
measure: Self-reported physical function
timeFrame: 3 months to 6 months
Other outcomes:
measure: Adherence to Energize program - video lessons viewed
timeFrame: 3 months
measure: Adherence to Energize program - planning or reporting exercise minutes
timeFrame: 3 months
measure: Adherence to Energize program - homework assignments
timeFrame: 3 months
Locations:
city: Columbia
country: United States
facility: University of South Carolina
state: South Carolina
Study officials:
References:
Clinical trial NCT06143527: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS
Official title: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
PCOS
Keywords: Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
PCOS
Stem Cell
Stem Cells
Mesenchymal Stem Cells
Umbilical Cord Derived Mesenchymal Stem Cells
Lead sponsor: The Foundation for Orthopaedics and Regenerative Medicine
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

Detailed description: Stem cell treatment has shown efficacy for PCOS in both human and animal studies. Complete resolution was seen of polycystic ovary syndrome (PCOS) in a young woman after a single intravenous injection of umbilical cord derived mesenchymal stem cells (UCDSC). It is hypothesized that intravenous infusion of UCDSC can reduce or eliminate PCOS. Patients will receive roughly 2 million umbilical cord derived mesenchymal stem cells per kg of body weight. Hormone levels and ultrasound will be checked 3,6 and 12 months after treatment.

Eligibility criteria: Inclusion Criteria:

• Ultrasound documented poly cystic ovary syndrome

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety
* Continued drug abuse
* Previous organ transplant
* Hypersensitivity to sulfur
* Inability to supply proper informed consent

Primary outcomes:
measure: Safety: Adverse Events
timeFrame: Four year follow-up
Secondary outcomes:
measure: Efficacy: Global Improvement Score (GI)
timeFrame: Four year follow-up
Other outcomes:
Locations:
city: St. John's
country: Antigua and Barbuda
facility: Medical Surgical Associates Center
city: Glyfáda
country: Greece
facility: Athens Beverly Hills Medical Group
Study officials:
affiliation: The Foundation for Orthopaedics and Regenerative Medicine
name: Chadwick C Prodromos, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01347827: Tissue Oxygenation During Heart Surgery
Official title: Comparison of Cerebral Tissue Oxygen Desaturation in Patients Undergoing On-pump or Off-pump Coronary Artery Bypass Grafting
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Bypass Grafting
Keywords: Coronary artery bypass surgery
Oximetry
Brain metabolism
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
First posted: 2011-05-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 60 consecutive adult patients scheduled for elective CABG surgery will be randomized to have the surgery performed either on-pump (n=30) or off-pump CABG (n=30).

Brief summary: The goal of this study is to determine if off-pump CABG surgery is associated with better cerebral tissue oxygenation when compared with on-pump CABG. In addition, the investigators would like to compare the results of two different monitors of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation (ScvO2). Finally, the investigators aim to determine if duration and extent of cerebral oxygen desaturation predict outcome variables such as postoperative cognitive performance.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Informed patient consent
* Coronary artery disease suitable for both on-pump and off-pump CABG surgery.

Exclusion Criteria:

* History of head trauma or stroke causing significant active neurologic disease
* History of neurosurgery
* Severe or symptomatic carotid artery disease
* Requirement for valve surgery in addition to CABG
* Pre-existing acute or chronic renal dysfunction
* Urgent or emergency surgery
* Difficulty with cognitive testing: impaired hearing or eyesight, poor Dutch language comprehension, disability impairing the usage of the hand or arm.

Primary outcomes:
measure: incidence of significant brain tissue oxygen desaturation, defined as AUC40 > 600 %.sec (a function of both duration (in seconds) and severity (saturation < 40%) of desaturation).
timeFrame: 3 months
Secondary outcomes:
measure: Oxygenation measurements: Peripheral muscle StO2, cerebral and renal StO2, ScvO2, SaO2, arteriovenous oxygen difference, pO2 Acid-base status: pH, pCO2, HCO3-, ABE, lactate
timeFrame: 3 months
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
Study officials:
affiliation: University Medical Center Groningen
name: Thomas W.L. Scheeren, Prof.dr
role: PRINCIPAL_INVESTIGATOR
References:
citation: de Keijzer IN, Poterman M, Absalom AR, Vos JJ, Mariani MA, Scheeren TWL. Comparison of renal region, cerebral and peripheral oxygenation for predicting postoperative renal impairment after CABG. J Clin Monit Comput. 2022 Jun;36(3):735-743. doi: 10.1007/s10877-021-00701-4. Epub 2021 Apr 20.